{"id":"quadrivalent-influenza-virus-subunit-vaccine","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Injection site pain, redness, or swelling"},{"rate":"5–15","effect":"Myalgia (muscle pain)"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Fatigue"},{"rate":"1–5","effect":"Low-grade fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The vaccine contains purified viral subunits from four circulating influenza strains, which are presented to the immune system to elicit both humoral (antibody) and cellular immune responses. This preparation allows the body to recognize and mount a rapid, protective response upon exposure to wild-type influenza virus, reducing infection risk and disease severity.","oneSentence":"A quadrivalent inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus (two A subtypes and two B lineages).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:04.297Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children"}]},"trialDetails":[{"nctId":"NCT05645900","phase":"PHASE3","title":"A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2023-02-06","conditions":"Influenza","enrollment":2772},{"nctId":"NCT06015282","phase":"PHASE3","title":"The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-11-03","conditions":"Influenza, Human","enrollment":7741},{"nctId":"NCT03932682","phase":"PHASE3","title":"Efficacy Study With QIVc in Pediatric Subjects","status":"COMPLETED","sponsor":"Seqirus","startDate":"2019-05-13","conditions":"Influenza, Human","enrollment":5723},{"nctId":"NCT03849560","phase":"PHASE2, PHASE3","title":"Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers","status":"COMPLETED","sponsor":"NPO Petrovax","startDate":"2016-11","conditions":"Influenza","enrollment":612},{"nctId":"NCT04782323","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2021-04-13","conditions":"Influenza","enrollment":839},{"nctId":"NCT04576702","phase":"PHASE2","title":"Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2020-10-08","conditions":"Influenza, Human","enrollment":471},{"nctId":"NCT05501561","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2022-08-25","conditions":"Influenza, Human","enrollment":1056},{"nctId":"NCT05047770","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-07","conditions":"Herpes Zoster","enrollment":2013},{"nctId":"NCT01964989","phase":"PHASE3","title":"Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.","status":"COMPLETED","sponsor":"Seqirus","startDate":"2013-11","conditions":"Influenza Virus","enrollment":10644},{"nctId":"NCT02255409","phase":"PHASE3","title":"Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05","status":"COMPLETED","sponsor":"Seqirus","startDate":"2014-10","conditions":"Influenza","enrollment":607},{"nctId":"NCT04192500","phase":"PHASE2","title":"Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years","status":"COMPLETED","sponsor":"Osivax","startDate":"2019-12-11","conditions":"Influenza","enrollment":300},{"nctId":"NCT04074928","phase":"PHASE3","title":"Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects","status":"COMPLETED","sponsor":"Seqirus","startDate":"2019-09-06","conditions":"Influenza, Human, Virus Diseases","enrollment":2414},{"nctId":"NCT03553940","phase":"PHASE1","title":"H3N2 M2SR in Pediatric Population","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-08-15","conditions":"Influenza, Influenza Immunisation","enrollment":43},{"nctId":"NCT03165617","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2017-05-25","conditions":"Influenza, Human","enrollment":4514},{"nctId":"NCT02583256","phase":"PHASE3","title":"Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)","status":"COMPLETED","sponsor":"Seqirus","startDate":"2016-01-29","conditions":"Influenza","enrollment":1601},{"nctId":"NCT01992094","phase":"PHASE3","title":"Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-11","conditions":"Influenza","enrollment":2680},{"nctId":"NCT01992107","phase":"PHASE3","title":"Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-11","conditions":"Influenza","enrollment":2333}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Quadrivalent influenza virus subunit vaccine","genericName":"Quadrivalent influenza virus subunit vaccine","companyName":"Ab&B Bio-tech Co., Ltd.JS","companyId":"ab-b-bio-tech-co-ltd-js","modality":"Biologic","firstApprovalDate":"","aiSummary":"A quadrivalent inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus (two A subtypes and two B lineages). Used for Seasonal influenza prevention in adults and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}